Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
European Child & Adolescent Psychiatry|April 3, 2007
Long-acting medications for the hyperkinetic disorders. A note on cost-effectivenessMichael SchlanderInternational Journal of Health Policy and Management|July 3, 2020
HTA Agencies Need Evidence-Informed Deliberative Processes Comment on "Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"Michael SchlanderCurrent Medical Research and Opinion|January 12, 2008
Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD)Michael SchlanderCurrent Pharmaceutical Design|June 2, 2010
The pharmaceutical economics of child psychiatric drug treatmentMichael SchlanderChild and Adolescent Psychiatry and Mental Health|January 17, 2008
The NICE ADHD health technology assessment: a review and critiqueMichael SchlanderChild and Adolescent Psychiatry and Mental Health|November 17, 2007
Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidenceMichael SchlanderZeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 9, 2010
Measures of efficiency in healthcare: QALMs about QALYs?Michael SchlanderCurrent Medical Research and Opinion|January 31, 2007
NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD)Michael SchlanderZeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|May 30, 2009
[Health economics: in search of efficiency]Michael SchlanderMedizinische Klinik (Munich, Germany : 1983)|June 22, 2005
[Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG]Michael SchlanderPageof 7